Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Choriogonadotropin alfa + biotin** is a combination product that would contain both choriogonadotropin alfa, a recombinant form of human chorionic gonadotropin hormone used primarily to induce ovulation and treat female infertility, and biotin, a water-soluble B vitamin (vitamin B7) known as a coenzyme for carboxylase enzymes involved in fatty acid synthesis, amino acid metabolism, and gluconeogenesis. Choriogonadotropin alfa works by binding to and activating the luteinizing hormone/chorionic gonadotropin receptor, mimicking the action of endogenous luteinizing hormone to induce ovulation in females. Biotin serves as an essential cofactor for metabolic enzymes and is clinically relevant for treating or preventing biotin deficiency, but is not a standard treatment for infertility or reproductive indications. There is no evidence of a marketed or clinically developed combination of these two agents; this entry describes their known pharmacology as monocomponents[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on choriogonadotropin alfa + biotin.